Android app on Google Play

Teva (TEVA) Launches Generic ACTOplus met

August 17, 2012 3:26 PM EDT Send to a Friend
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of an authorized generic of ACTOplus met (pioglitazone/metformin tablets)15 mg/500 mg, 15 mg/850 mg.

ACTOplus met is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOplus met® had annual sales of approximately $413 million in the United States, based on IMS sales data as of June 30, 2012.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment